Phase III study of Fycompa (Eisai) shows low discontinuation rates in Epilepsy treatment

New data on the safety, efficacy and impact on quality of life of Fycompa (perampanel), from Eisai, as treatment in partial-onset Epilepsy highlighted the low discontinuation rates during long-term treatment. Data from over 1000 patients from Phase III trials who received adjunctive perampanel treatment for 24 weeks showed that the total discontinuation rates declined over time, from 7.9 % at 24-36 weeks to 2.0% at 72 weeks and this was mirrored by a decline in rates of discontinuation due to adverse events (AEs) from 2.6% at 24-36 weeks to 0.8% at 72 weeks. The most common reasons were patient choice, inadequate therapeutic effects and AEs.

Additional 10 months safety and efficacy data from study 307 shows that improvement occurred in the first 26 weeks of treatment, as the drug was up-titrated. The responder rate was 32-35% at week 1-13 and 42-48% at weeks 14-26. Thereafter, the seizure outcomes were stable. Data were presented at the 30th International Epilepsy Congress.